Besides its potential as an applicant for targeted therapy [19,20], PET imaging using a 64Cu- or 89Zr-labeled monoclonal antibody against MSLN as well as subsequent therapeutical usage of anti-mesothelin antibody-drug conjugate treatment has shown promising results in pancreatic and/or ovarian cancer [21,22]. The gene discussed is MSLN; the disease is ovarian cancer.